Citations

Clear

4510 citation(s) found for "Scott, C".

Role of a Deep‐Learning Based Convolutional Neural Network Model for Real‐Time Ventricular Tachycardia Alarm Classification
Khanolkar, U K, Yadav, Ashish, Mann, Avdhesh, Pappada, Scott , Deshmukh, Abhishek, Maan, Abhishek , Yadav, Ashish , Yadav, Ashish

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 27, 2026 | Volume: 37 | Issue: 4 | Pages: 705-713

10.1111/jce.70271 | PMID 41588600 Get It

ABSTRACT Background Ventricular tachycardia (VT) is a life‐threatening arrhythmia that requires both relatively rapid and accurate detection in intensive care units (ICUs). Continuous monitoring systems play a crucial role in detecting them. However, previous studies have reported that nearly 9 out of 10 arrhythmia alarms in ICUs tend to be false positives, which usually transpire to a well‐documented phenomenon called “alarm fatigue” that leads to desensitization, delayed responses, and increased cognitive burden on healthcare providers. Methods We developed a deep learning based, one‐dimensional convolutional neural network (1D‐CNN) to classify VT alarms using multiple raw waveform inputs, including two electrocardiogram (ECG) leads, photoplethysmogram (PPG) and arterial blood pressure (ABP) signals. The model was trained using the publicly available VTaC Arrhythmia Benchmark Dataset. We used the 10‐second waveform segments that preceded each VT alarm, pre‐processed and then used them to train the machine learning model to correctly classify the VT alarm. Results On the test set, the model achieved an area under the receiver operating characteristic curve of 0.901, overall accuracy of 83.22%, F1‐score of 73.3%, sensitivity of 77.53%, specificity of 85.63%, and positive predictive value of 69.57%. The model successfully detected over three‐quarters of them while significantly reducing false positive rates for the detection of VT. Conclusions This study demonstrates that a deep learning based 1D‐CNN model using short segments of raw waveform data can achieve robust performance in distinguishing true and false VT alarms.
Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer’s disease
Chiotis, Konstantinos, Soleimani-Meigooni, David N, Aisen, Paul S, Amuiri, Alinda, Atri, Alireza, Beckett, Laurel, Brickhouse, Michael , Clark, David G, Dage, Jeffrey L, Day, Gregory S, Duara, Ranjan, Eloyan, Ani , Foroud, Tatiana, Graff-Radford, Neill R, Grant, Ian M, Hammers, Dustin B, Honig, Lawrence S, Johnson, Erik C. B., Jones, D. Richard, Kirby, Kala, Koeppe, Robert, Kramer, Joel H, Kukull, Walter A, Leuzy, Antoine , Masdeu, Joseph C., Mendez, Mario F., Musiek, Erik, Nudelman, Kelly N., Onyike, Chiadi U., Riddle, Meghan, Rocha, Salma, Rogalski, Emily, Salloway, Stephen, Schonhaut, Daniel R., Sha, Sharon, Shankar, Ranjani, Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W., Touroutoglou, Alexandra, Turner, Raymond Scott, Vemuri, Prashanthi, Wingo, Thomas S., Wolk, David A., Womack, Kyle, Zhang, J. , Carrillo, Maria C., Dickerson, Bradford C., Apostolova, Liana G., Joie, Renaud La, Rabinovici, Gil D., Chiotis, Konstantinos , Blazhenets, Ganna , Soleimani‐Meigooni, David N. , Aisen, Paul , Atri, Alireza , Beckett, Laurel , Clark, David G., Dage, Jeffrey L. , Day, Gregory S. , Duara, Ranjan , Foroud, Tatiana , Graff‐Radford, Neill R. , Hammers, Dustin B , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Koeppe, Robert A. , Kramer, Joel H. , Kukull, Walter A. , Lagarde, Julien , Maiti, Piyush , Masdeu, Joseph C , Mendez, Mario F. , Musiek, Erik , Nudelman, Kelly , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen, Schonhaut, Daniel R. , Sha, Sharon J. , Shankar, Ranjani , Taurone, Alexander, Thangarajah, Maryanne, Toga, Arthur W. , Touroutoglou, Alexandra , Turner, Raymond Scott , Vemuri, Prashanthi , Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D.

Mayo Clinic

No container title available | January 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.25.26344738 | PMID 41646765 Get It

Abstract Early-onset Alzheimer’s disease (EOAD) and Late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau PET burden, and their relationship with clinical variables in amyloid-PET positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD; n=390) and Alzheimer’s Disease Neuroimaging Initiative (LOAD; n=211). Patients with EOAD showed higher baseline tau PET retention, broader neuroanatomical involvement and faster accumulation rates over time compared to LOAD, after adjusting for amyloid load and clinical stage. Tau PET showed stronger correlations with baseline amyloid burden and clinical measures of global cognition and function in EOAD than LOAD. We conclude that earlier age of onset in AD is linked to a more aggressive tauopathy, which in turn is a primary driver of clinical decline. These findings suggest that optimal therapeutic targets and strategies may differ between EOAD and LOAD. One Sentence Summary Younger patients with Alzheimer’s disease show more aggressive tau spread, suggesting age of onset defines distinct disease pathways with key clinical implications.
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Stish, Bradley J. , Mazza, Gina L. , Nauseef, Jones T. , Humeniuk, Michael, Smith, Thomas J. , Tofthagen, Cindy, Pardo, D.A. Diaz, Chay, Christopher H., Huang, Andrew Jonathan, Naha, Kushal , Tagawa, Scott T., Chow, Selina , Ruddy, Kathryn, Lustberg, Maryam B. , Adams-Campbell, Lucile L., Novotny, Paul J. , Loprinzi, Charles L. , Tofthagen, Cindy , Diaz, Dayssy A. , Tofthagen, Cindy S , Sebastian, Nikhil T , Huang, Andrew J , Tagawa, Scott T , Ruddy, Kathryn J , Smith, Thomas J , Mazza, Gina L , Nauseef, Jones T , Lustberg, Maryam , Tagawa, Scott T. , Ruddy, Kathryn J. , Adams-Campbell, Lucile L.

Mayo Clinic

Journal of Clinical Oncology | January 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1198-1205

10.1200/jco-25-01486 | PMID 41587370 Get It

PURPOSE Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( P = .02), and 6.89 ( P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 ( P = .07), and 13.95 ( P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg ( P = .042) and 5 mg ( P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.
Disparities across the pediatric epilepsy surgery journey: Referral, recommendation, and completion from a national consortium
Berl, Madison M. , Wagner, Janelle L. , Caraway, Avery Robert, Loblein, Hayley , Novotny, Edward J. , Patrick, Kristina E. , Ostendorf, Adam P. , Alexander, Allyson , Eschbach, Krista , Depositario‐Cabacar, Dewi F., Vu, Thuy‐Anh , Karia, Samir R., Romanowski, Erin Fedak , Bolton, Jeffrey , Ailion, Alyssa , Tatachar, Priyamvada, Pichon, Pilar, Shrey, Daniel W. , Singh, Rani K., Lin, Jenny, Koop, Jennifer I. , Gonzalez‐Giraldo, Ernesto, Auguste, Kurtis I. , Bernardo, Danilo , Ciliberto, Michael A. , Reddy, Shilpa B. , Ganesh, Abhinaya, Arredondo, Kristen H. , Nangia, Srishti, Samanta, Debopam, Marashly, Ahmad , Armstrong, Dallas , Perry, M. Scott, Workgroup, the PERC Surgery, Caraway, Avery R. , Wagner, Janelle , Caraway, Avery Robert , Patrick, Kristina E , Alexander, Allyson L , Eschbach, Krista , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Karia, Samir , Karakas, Cemal , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Bolton, Jeffrey Brian , Ailion, Alyssa , Tatachar, Priyamvada , Pichon, Pilar D , Shrey, Daniel W , Coryell, Jason , Koop, Jennifer I , Gonzalez-Giraldo, Ernesto , Auguste, Kurtis I , Bernardo, Danilo , Ciliberto, Michael A , Reddy, Shilpa B , Ganesh, Abhinaya , Arredondo, Kristen H , Grinspan, Zachary , Nangia, Srishti , Samanta, Debopam , Armstrong, Dallas Michael , Perry, Michael Scott , Berl, Madison , Novotny, Edward J , Loblein, Hayley, Depositario‐Cabacar, Dewi, Oluigbo, Chima , Karia, Samir , Karakas, Cemal , Wong‐Kisiel, Lily C. , McNamara, Nancy , Tatachar, Priyamvada , Coryell, Jason , Gonzalez‐Giraldo, Ernesto , Grinspan, Zachary M. , Samanta, Debopam

Mayo Clinic

Epilepsia | January 24, 2026 | Volume: 67 | Issue: 4 | Pages: 1601-1613

10.1002/epi.70060 | PMID 41579031 Get It

Abstract Objective Despite being safe and effective, surgery for pediatric epilepsy is underutilized. Social determinants of health (SDoH) are important to consider when examining this treatment gap. This study examined the potential systemic inequities at three different stages in the journey toward epilepsy surgery across the Pediatric Epilepsy Research Consortium (PERC). Methods Any youth in the PERC prospective surgery database (≤18 years) was eligible and included if sociodemographic factors were also available. We examined if there were differences in disparity factors in: (1) referral to Phase I evaluation, (2) offering of surgery, and (3) completion of surgery. Results Of 1309 patients, the majority were male (53%, p = .04), White (82.2%, p < .001), not Hispanic or Latino (84.3%, p < .001), and privately insured (56.3%, p < .001). Of the youth who were offered surgical treatment ( n = 1103, 84.3%), there were no significant differences in race/ethnicity or sex. Those with a structural lesion were more likely to be offered surgery, and historically marginalized youth were more likely to have a lesion. Of patients who completed surgery ( n = 927, 84.0%), White patients were 1.88 times (95% confidence interval [CI]: 1.14–3.04) more likely than Black patients to complete surgery ( p = .01). Significance Youth who began surgery evaluation are not representative of the demographics of those with epilepsy in the United States, with greater representation of White, non‐Hispanic male individuals. In addition, youth who began surgery evaluation disproportionally have private insurance. At the next stage of offering surgery, there were no differences based on SDoH. However, there is evidence that underrepresented youth that were magnetic resonance negative were less likely to be referred for surgical workup and that Black youth were less likely to undergo surgery. Therefore, efforts to provide equitable opportunity for all youth with refractory epilepsy should be concentrated at the referral for surgery evaluation point of care; however, additional efforts are also needed at later stages.
Impact of Sleep Positioning Device on Acid Exposure and Outcomes in Lung Transplant Recipients With Gastroesophageal Reflux Disease
Aggarwal, Manik , Thuita, Lucy , Greathouse, Tyler, Rappaport, Jesse , Kichler, Adam, Arora, Zubin , Qin, Yi, Akindipe, Olufemi, Tang, Andrew , Murthy, SC, Lane, Charles, Budev, Marie, Ahmad, Usman, Gabbard, Scott , Lane, Charles Randall, Budev, Marie , Ahmad, Usman

Mayo Clinic

Journal of Clinical Gastroenterology | January 21, 2026 | Volume: 60 | Issue: 7 | Pages: 619-625

10.1097/mcg.0000000000002300 | PMID 41564033 Get It

Introduction: Gastroesophageal reflux disease (GERD) plays an important role in lung transplant (LT) outcomes. This study aims to evaluate the impact of a novel sleep positioning device (SPD) on lung function in LT recipients with GERD. Methods: In this single-center cohort study, LT recipients (2014 to 2019) with GERD who were prescribed an SPD within 2 years of LT were included. A historical control group of LT recipients with GERD on PPI only (2011 to 2013) was selected to compare forced expiratory volume in 1 second (FEV1) as a marker of lung function. Results: Twenty LT recipients using SPD (cases) and 54 patients in the historical control group with proven GERD were included. Mean (SD) interval between LT and SPD prescription was 8.6 (5.7) months. Mean % predicted FEV1 was higher in SPD users than controls post-LT at 6 months (80% vs. 69%) and 1 year (80% vs. 71%), respectively. Among SPD users, post-SPD FEV1 was higher than pre-SPD FEV1 (82% vs. 70%). Conclusion: Use of a novel SPD can stabilize or improve pulmonary function in patients with GERD after LT. SPD may be a safe and cost-effective adjunctive therapy for the management of GERD after LT.
Western pediatric cervical spine study: an observational prospective Western Pediatric Surgery Research Consortium and Western Trauma Association multicenter study protocol
Kahan, Anastasia Morgan, Padilla, Benjamin E, Patwardhan, Utsav M , Larsen, Kezlyn, Lee, Justin H, Ostlie, Daniel J. , Jensen, Aaron R. , Ignacio, Romeo C. , Chao, Stephanie D. , Ravindra, Vijay M. , Swendiman, Robert A. , Iyer, Rajiv R. , Brockmeyer, Douglas L. , Kelley-Quon, Lorraine I, Yorkgitis, Brian K. , Inaba, Kenji, Kahan, Anastasia M , Kahan, Anastasia Morgan , Chao, Stephanie D , Russell, Katie , Eldredge, R Scott , Padilla, Benjamin E. , Presson, Angela P. , Melhado, Caroline G. , Kelley‐Quon, Lorraine I. , Escobar, Mauricio Antonio , Inaba, Kenji , Russell, Katie W.

Mayo Clinic

Trauma Surgery & Acute Care Open | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: e001728

10.1136/tsaco-2024-001728 | PMID 41573663 Get It

Background In pediatric patients presenting after blunt trauma, the incidence of clinically significant cervical spine injury (CSI) is approximately 1%. Although multidetector CT (MDCT) is widely accepted for cervical spine clearance in adults, its utility in children remains uncertain. The purpose of this study is to evaluate the sensitivity of MDCT in identifying clinically significant CSI in pediatric patients, stratified by age groups: adolescents (12 years to 17 years) and children (0 years to 11 years). Methods We designed a national, multicenter, prospective observational study to assess the diagnostic performance of MDCT in detecting clinically significant CSI in pediatric trauma patients. Data are being collected from participating centers on imaging findings, clinical outcomes, and the presence of confirmed CSIs after blunt trauma. The analysis plan includes stratification by age group and calculation of sensitivity, specificity, and predictive values of MDCT for CSI. Results This abstract outlines the background, methodology, and analytical framework of the study. Data collection and analysis are ongoing. This study represents the largest known cohort of pediatric patients undergoing cervical spine imaging after blunt trauma and is the first prospective study of its kind focused exclusively on this population. Conclusions This study will provide critical data to inform guidelines for pediatric cervical spine clearance after blunt trauma. By evaluating the sensitivity of MDCT in detecting clinically significant CSI, the findings aim to support evidence-based imaging strategies and improve the safety and efficiency of pediatric trauma care.
Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference
Field, Thalia S., Morton, Sarah U. , Brossard‐Racine, Marie , Cohen, Scott , Feldman, Howard , Chung, Ai Wern , Newburger, Jane W., Puder, Rick, Gurvitz, Michelle , Cassidy, Adam, Newburger, Jane W. , Field, Thalia S. , Field, Thalia S , Feldman, Howard H , Newburger, Jane W , Cassidy, Adam R , Cassidy, Adam R.

Mayo Clinic

Journal of the American Heart Association | January 19, 2026 | Volume: 15 | Issue: 2 | Pages: No page available

10.1161/jaha.125.042617 | PMID 41553060 Get It

With improvement in medical and surgical care, the number of adults with congenital heart disease (CHD) is soaring. Adults with CHD commonly have impairments in brain health. However, significant gaps in knowledge remain regarding the relevant types and prevalence of neurologic and psychiatric risk and their associated risk factors. We sought to review current evidence, identify gaps in knowledge, and develop key next steps to improve scientific understanding and clinical care. Three working groups—Genetics and Brain Health, Characterizing Neuropsychological and Psychological Outcomes, and Neuropsychological and Psychosocial Interventions—were composed of multidisciplinary experts in relevant clinical and research domains, as well as adults with CHD. Each group identified 5 key knowledge gaps and associated next investigations needed to address those gaps. For Genetics and Brain Health, 5 key knowledge gaps were identified: lack of a standardized neuroimaging protocol for adults with CHD, need to understand neuroradiological–pathological–neuropsychological correlates, role of gene–environment interactions, what can be learned from brain health risk models from other groups, and how existing multimodal approaches influence risk and neuroresilience. Adults with CHD can benefit from routine assessment of brain health, as well as increased clinical and basic research into the underlying factors that contribute to risk and neuroresilience for neurologic and psychiatric sequalae. Multidisciplinary collaborative efforts that incorporate adults with CHD across the research cycle are essential for all key next steps.
Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig
Wilken, Silvana, Minshew, Anna, Ahmadzada, Boyukkhanim , Hosseiniasl, Seyed M. , Kazeminia, Sara , Ezenekwe, Kachi, Patil, Ameya, Park, Byoung Uk , Sultan, Ahmer, Smith, L. Glenn, Correa, Julio Cisneros, Hussein, Kamal Hany , Moreira, Roger, Nyberg, Scott L. , Wilken, Silvana N , Felgendreff, Philipp , Kazeminia, Sara , Park, Byoung U , Cisneros Correa, Julio, Hussein, Kamal, Moreira, Roger K. , Nyberg, Scott L , Minshew, Anna, Ezenekwe, K., Patil, Ameya , Sultan, Ahmer, Smith, Lindsey, Hussein, Kamal Hany , Malhi, Harmeet

Mayo Clinic

Veterinary Pathology | January 17, 2026 | Volume: 63 | Issue: 4 | Pages: 746-756

10.1177/03009858251411305 | PMID 41546493 Get It

Metabolic dysfunction-associated steatohepatitis (MASH) is a global health care burden. Appropriate large animal models mimicking the main MASH characteristics of steatosis, inflammation, and hepatocyte damage alongside progression of fibrosis are imperative for robust preclinical studies, especially in the field of hepatobiliary surgery. The present study aimed to characterize a novel model of steatohepatitis in fumarylacetoacetate hydroxylase-deficient ( FAH -/- ) pigs. FAH -/- pigs were generated using a CRISPR/Cas9 system. The animals received a choline-deficient, L-amino acid-defined high-fat diet and subtherapeutic doses of nitisinone and were followed for 3 months. Liver biopsies were obtained at baseline and every month during treatment. Steatosis, inflammation, and fibrosis were assessed by conventional histological scoring systems and by an artificial intelligence (AI) model. Serum liver parameters were analyzed every 2 weeks. Steatosis increased significantly throughout the study, with severe steatosis observed as early as 2 months into treatment. The inflammation score was increased in all animals after 3 months of treatment, whereas the AI-based CD45+ cell count showed region-specific trends in the portal and lobular areas. Collagen content and the corresponding fibrosis stage showed an increase over the 3-month period; however, the difference was not significant. Serum liver parameters did not show any relevant elevations during the study. In summary, we successfully developed and characterized a novel model of steatohepatitis in the FAH -/- pig within 3 months. Further studies with prolonged observation time and/or cycling of nitisinone administration are needed to evaluate whether progressive fibrosis and cirrhosis could be achieved with this model.
Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP
Best, Simon R. , Friedman, Aaron D. , Rosen, Clark A., Sataloff, Robert T. , Matrka, Laura , Sims, H. Steven , Rosow, David E. , Lott, David G., Mau, Ted, Wikenheiser‐Brokamp, Kathryn A., Norberg, Scott M. , McClellan, Kim, Young, Geoffrey D., ALLEN, C., Lott, David G. , Wikenheiser‐Brokamp, Kathryn A. , Mau, Ted , Rosen, Clark , Matrka, Laura , Lott, David G , Mau, Ted , Allen, Clint T , Amin, Milan R , Saba, Nabil F. , Klein, Adam M.

Mayo Clinic

The Laryngoscope | January 16, 2026 | Volume: 136 | Issue: S4 | Pages: No page available

10.1002/lary.70379 | PMID 41543033 Get It

ABSTRACT Objective With regulatory approval of HPV‐specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. Data Sources and Methods RRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm for adults with RRP considering published literature and commercial drug availability. Results Preventative HPV vaccination should be considered for all patients. Determination of HPV type and pulmonary imaging are important for contemporary RRP patient care and assist in decision making. Risks and benefits of papilloma debulking as needed versus medical management of RRP must be deliberated on a patient case‐by‐case basis. HPV ‐specific immunotherapy that induces an HPV ‐specific T cell response to target the underlying HPV infection that is the cause of RRP is safe, offers the possibility of durable disease control following a short treatment course and is the recommended first‐line medical treatment for patients who wish to avoid the risks of repeat procedural management. Papilloma disease control with systemic bevacizumab, which carries defined risks and must be continued for clinical benefit is the recommended second‐line medical treatment for patients who do not achieve a complete response with immunotherapy and wish to continue medical management. For patients who elect to be treated with debulking procedures as needed, use of locally‐administered adjuvant should be considered. Conclusion This proposed management algorithm from the RRPF serves as a contemporary resource and information guide for adult patients with RRP and their physicians considering treatment options. Level of Evidence 5